The responsibilities and procedures applicable to the quality control unit are not in writing.
Inspection Record
L' Oreal Usa, Inc. — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Labels and other labeling materials are not stored separately with suitable identification for each different drug product, strength, dosage form or quantity of contents.
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the holding of rejected components, drug product containers, closures and labeling before disposition.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- CoreRX Inc.2025-03-20 · US FDASimilar to finding 1 The responsibilities and procedures applicable to the quality control unit are not in writing.
- Revance Therapeutics, Inc.2021-07-02 · US FDASimilar to finding 1 The responsibilities and procedures applicable to the quality control unit are not always in writing.
- California Stem Cell Treatment Center/Cell Surgical Network2018-05-09 · US FDASimilar to finding 1 The responsibilities and procedures applicable to the quality control unit are not in writing.
- Paxeuticals LLC2026-04-20 · US FDASimilar to finding 1 The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
- Neva Analytics, LLC2026-04-01 · US FDASimilar to finding 1 The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.